Ibrutinib plus venetoclax is recommended as an option for untreated chronic lymphocytic leukaemia (cll) or small lymphocytic lymphoma (sll) in adults Ibrutinib plus venetoclax achieved higher undetectable mrd rates and extended pfs compared to ibrutinib alone or fcr in cll patients All the criteria as described in the appropriate blueteq form are met and an application for use has been approved.
"Se vienen las fiestas y quiero estar perfecta": Faloon Larraguibel
Retreatment with ibrutinib or acalabrutinib was effective for patients who experienced disease relapse.
